Иммуносупрессия: необходимость и возможность защиты пациентов от инфекций вакцинацией

Иммуносупрессия: необходимость и возможность защиты пациентов от инфекций вакцинацией

Автор: Каральник Б. В., Рамм А. Н.

Журнал: Вестник гематологии @bulletin-of-hematology

Рубрика: Оригинальные статьи

Статья в выпуске: 1 т.15, 2019 года.

Бесплатный доступ

Иммуносупрессия, обусловленная многими заболеваниями и/или необходимыми средствами лечения, приводит к повышенной восприимчивости к инфекциям, более тяжёлому их течению, более частым инвалидизации и летальности. Защита таких пациентов от инфекций методами вакцинации уменьшает указанные риски. В обзоре обсуждаются используемые сегодня дефиниции «целевые группы» и «группы риска». На многих примерах представлены размеры наносимого инфекциями урона в группах риска (пациенты с иммуносупрессией) в сравнении суроном в общей популяции, возможности и оценка эффективности вакцинации групп риска. По результатам различных исследований рассмотрены особенности схем вакцинации групп риска в сравнении с вакцинацией целевых групп в общей популяции.

Еще

Иммуносупрессия, инфекции, урон от инфекций, вакцинация, эффективность

Короткий адрес: https://sciup.org/170172551

IDR: 170172551

Список литературы Иммуносупрессия: необходимость и возможность защиты пациентов от инфекций вакцинацией

  • Burroughs M, MosconaA. Immunization of pediatric solid organ transplant candidates and recipients// Clin Infect Dis 2000; v.30:857-869. https://doi.org/10.1086/313823
  • Davies K, Woo P. Immunization in rheumatic diseases of childhood: an audit of the clinical practice of British Paediatric Rheumatology Group members and review of the evidence. Rheumatology (Oxford) 2002; v.41: 937-941. https://doi.org/10.1093/rheumatology/41.8.937
  • Bridges MJ, Coady D, Kelly CA, Hamilton J, Heycock C. Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis//Ann Rheum Dis 2003; v.62 № 7:680-681. http://dx.doi.org/10.1136/ ard.62.7.685;
  • Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Medicine (Baltimore). 2016 Jul; 95(27): e4012. Published online 2016 Jul 8. doi: 10.1097/MD.0000000000004012;
  • Rubin L. G., Levin M.J., Ljungman P., Davies E. G., Avery R. et al. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. Clin Infect Dis. 2014 Feb;58(3):309-18. doi: 10.1093/cid/ cit816.
  • Vento S, Cainelli F. Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment//Lancet Oncology 2003 v.4: 595-604. https://doi.org/10.1016/S1470-2045(03)01218-X;
  • Yaguchi T, Kawakami Y. Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol. 2016 Aug;28(8):393-9. doi: 10.1093/intimm/dxw030. Epub 2016 Jul 8.
  • Shildt, R. A., Luedke, D. W., Laham, M. N., Kasai, G. and El-Beheri, S. (1979), Antibody response to influenza immunization in adult patients with malignant disease. Cancer, 44: 1629-1635. doi:10.1002/1097-0142(197911)44:5 - 1629:: AID-CNCR2820440514 - 3.0.C0;2-7
  • Danerseau AM, Robinson JL. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs. World J Pediatr. 2008 Nov;4(4):254-8. doi: 10.1007/s12519-008-0047-1. Epub 2008 Dec 23.
  • Ljungman, P., Lewensohn-Fuchs, I., Hammarstrom, V., Aschan, J., Brandt, L., Bolme, P., Lonnqvist, B., Johansson, N., Ringden, O., & Gahrton, G. (1994). Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood, 84(2), 657-663.
  • Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant. 1999 Apr;23(7):637-46.
  • Alanko S, Pelliniemi TT, Salmi TT. Recovery of blood B-lymphocytes and serum immunoglobulins after chemotherapy for childhood acute lymphoblastic leukemia. Cancer. 1992 Mar 15;69(6):1481-6.
  • Engelhard, D., Cordonnier, C., Shaw, P. J., Parkalli, T., Guenther, C., Martino, R., Dekker, A. W., Prentice, H. G., Gustavsson, A., Nurnberger, W., Ljungman, P. and the Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT) (2002). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. British Journal of Haematology, 117: 444-450. doi:10.1046/j.1365-2141.2002.03457.x
  • Kumar D, Humar A, Plevneshi A, Siegal D, Franke N, Green K, McGeer A. Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant. 2008 Apr;41(8):743-7. doi: 10.1038/sj.bmt.1705964. Epub 2008 Jan 7.
  • Torda A, Chong Q, Lee A, Chen S, Dodds A, Greenwood M, Larsen S, Gilroy N. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2014 Oct;16(5):751-9. doi: 10.1111/tid.12268. Epub 2014 Jul 21.
  • Avery RK, Michaels M. Update on immunizations in solid organ transplant recipients: what clinicians need to know. Am J Transplant. 2008 Jan;8(1):9-14. Epub 2007 Dec 18. DOI: 10.1111/j.1600-6143.2007.02051.x
  • Munoz P., Rodriguez C., Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005 Feb 15;40(4):581-7. Epub 2005 Jan 25. https://doi.org/10.1086/427692
  • Batista MV, Pierrotti LC, Abdala E, Clemente WT, Giräo ES et al. Endemic and opportunistic infections in Brazilian solid organ transplant recipients. Trop Med Int Health. 2011 Sep;16(9):1134-42. doi: 10.1111/j.1365-3156.2011.02816.x.
  • Helfrich M, Dorschner P, Thomas S, Stosor V, Ison MG. A retrospective study to describe the epidemiology and outcomes of opportunistic infections after abdominal organ transplantation. Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12691.
  • HammarströmV, Pauksen K, Azinge J, Oberg G, LjungmanP.Pneumococcal immunity and response to immunization with pneumococcal vaccine in bone marrow transplant patients: the influents of graft versus host reaction. Support Care Cancer. 1993 Jul;1(4):195-9.
  • Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009 Oct;44(8):521-6. doi: 10.1038/bmt.2009.263.
  • Kennedy LB, Li Zh, Savani BN, Ljungman P. Measuring immune response to commonly used vaccination in adult recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2017 0ct;23(10):1614-1621. doi: 10.1016/j.bbmt.2017.06.006.
  • Wong A1, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ. Increased risk of invasive pneumococcal disease in hematological in solid-organ malignancies. Epidemiol Infect. 2010 Dec;138(12):1804-10. doi: 10.1017/ S0950268810000919.
  • Nichols L, Saunders R, Knollmann FD. Causes of death of patients with lung cancer. Arch Pathol Lab Med. 2012 Dec;136(12):1552-7. doi: 10.5858/arpa.2011-0521-0A.
  • Bitterman R, Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunocompromised adults with cancer. Cochrane Database Syst Rev. 2018 Feb 1;2: CD008983. doi: 10.1002/14651858.CD008983.pub3.
  • Alkan A, Karci E, Ya^ar A, Tuncay G, Köksoy EB et al. Vaccination in oncology practice and predictors. Support Care Cancer. 2017 Sep;25(9):2677-2682. doi: 10.1007/s00520-017-3675-y.
  • Avci N, Hartavi M, Ka^an T, Bayindir M, Avci M et al. Retrospective analysis of the microbiological spectrum of pneumonia in Turkish patients with lung cancer. Contemp Oncol (Pozn). 2016;20(1):63-6. doi: 10.5114/ wo.2016.58502.
  • Kaplan LI, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA. 1992 Mar 4;267(9):1237-41.
  • Ward EM, Flowers CR, Gansler T, Omer SB, Bednarczyk RA. The importance of immunization in cancer prevention, treatment and survivorship. CA Cancer J Clin. 2017 Sep;67(5):398-410. doi: 10.3322/ caac.21407.
  • Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, antitumor necrosis factor a, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1016-26. doi: 10.1002/acr.22246.
  • Rakoczi E, Szekanecz Z. Pneumococcal vaccination in autoimmune rheumatic diseases. RMD Open. 2017 Sep 14;3(2): e000484. doi: 10.1136/rmdopen-2017-000484.
  • Hernández-Cruz B, Cardiel MH, Villa AR, Alcocer-Varela J. Development, recurrence and severity of infections in Mexican patients with rheumatoid arthritis. A nested case-control study. J Rheumatol. 1998 0ct;25(10):1900-7.
  • Franklin J, Lunt M, Bunn D, Symmons D, SilmanA. Risk and predictors of infection leading to hospitalization in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis. 2007 Mar; 66(3): 308-312. doi: 10.1136/ard.2006.057265
  • Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001 Sep;13(5):345-51.
  • Gharibdoost F, Akbarian S, Akbarian M, Shahram F, Nadji A et al. Evaluation of the mortality in systematic lupus erythematosus (SLE) analysis 0f 2021 patients. Acta Medica Iranica 2003. 41(1):62-65.
  • Kuchar E, Miskiewicz K, Karlikowska M. A review of guidance on immunization in persons with defective of deficient splenic function. Br J Haematol. 2015 Dec;171(5):683-94. doi: 10.1111/bjh.13660.
  • Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N et al. Mortality associated with influenza and repiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289 (2):179-86.
  • CDC. Estimates of death associate with seasonal influenza — United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; v.59:1057-1062;
  • CDC. Prevention and control of seasonal Influenza with vaccines recommendations of the Advisory Committee on Immunization Practices — United States, 2016-17 influenza season//MMWR2016 v.65 №5:1-53;
  • Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population Arch Intern Med. 2005 Feb 14;165(3):265-72. DOI: 10.1001/archinte.165.3.265
  • Murasko DM, Bernstein ED, Gardner EM, Gross P, Munk G et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp Gerontol. 2002 Jan-Mar;37(2-3):427-39.
  • Weisser M, Theilacker C, Tschudin Sutter S, Babikir R, Bertz H et al. Secular trends of bloodstream infections during neutropenia in 15181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS). Clin Microbiol Infect. 2017 23(11):854-859. doi: 10.1016/j. cmi.2017.03.020. Epub 2017 Mart 31.
  • Klastersky J. Science and pragmatismin the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998 Jun;41 Suppl D:13-24.
  • Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignances and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003 May 1;36(9):1103-10. DOI: 10.1086/374339
  • Karanwal AB, Parikh BJ, Goswami P, Panchal HP, Parekh BB and Patel KB. Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospective analysis from a single center. Indian J Med Paediatr Oncol. 2013 Apr-Jun; 34(2): 85-88. doi: 10.4103/0971-5851.116184
  • Ministry of Health. 2017. Immunisation Handbook 2017. Wellington: Ministry of Health. Available at: https://www.health.govt.nz/publication/immunisation-handbook-2017 (accessed 08.03.2018)
  • Small TN, Cowan MJ. Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Rev Clin Immunol. 2011 Mar; 7(2):193-203. doi: 10.1586/eci.10.103.
  • Tomblyn M1, Chiller T, Einsele H, Gress R, Sepkowitz K et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. doi: 10.1016/j.bbmt.2009.06.019.
  • Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011 May;6(5):1192-7. doi: 10.2215/ CJN.05430610.
  • Perez-Romero P, Aydillo TA, Perez-Ordoñez A, Muñoz P, Moreno A et al. Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect. 2012 Dec;18(12): E533-40. doi: 10.1111/1469-0691.12044. Epub 2012 Oct 19.
  • Hung TY, Kotecha RS, Blyth CC, Steed SK, Thornton RB et al. Immunogenicity and safety of single-dose, 13-valent pneumococcal conjugate vaccine in pediatric and adolescent oncology patients. Cancer. 2017 Nov 1;123(21):4215-4223. doi: 10.1002/cncr.30764. Epub 2017 Jul 11.
  • Cordonnier C, Labopin M, Chesnel V, Ribaud P, De La Camara R et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009 May 15;48(10):1392-401. doi: 10.1086/598324.
  • Jaffe D, Papadopopoulos EB, Yang JW, O'reilly RJ, Prockop S et al. Immunogenecity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood. 2006 Oct 1;108(7):2470-5. DOI: 10.1182/blood-2006-04-006981.
  • Cordonnier C, Labopin B, Robin C, Ribaud P, Cabanne L et al. Long-term persistence of the immune response to antipneumococcal vaccines after allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. Bone Marrow Transplant. 2015 Jul;50(7):978-83. doi: 10.1038/bmt.2015.42.
  • Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006 Jan;45(1):106-11. DOI: 10.1093/rheumatology/ kei193.
  • Kapetanovic MC, Roseman C, Jönsson G, Truedsson L, Saxne T, GeborekP.Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated with tumor necrosis factor inhibitors. Arthritis Rheum. 2011 Dec;63(12):3723-32. doi: 10.1002/art.30580.
  • Bingham CO, Rizzo W, Kivitz A, Hassanali A, Upmanyu R, Klearman M. Humoral immune response to vaccines inpatients with rheumatoid arthritis treated with tocilizumab: results of a randomized controlled trial (VISARA). Ann Rheum Dis. 2015 May;74(5):818-22. doi: 10.1136/annrheumdis-2013-204427.
  • Alten R, Bingham CO, Cohen SB, Curtis JR, Kelly S, Wong D, Genovese MC. Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept. BMC Musculoskelet Disord. 2016 May 26;17:231. doi: 10.1186/s12891-016-1082-z.
  • Izumi Y, Akazawa M, Akeda Y, Tohma S, Hirano F et al. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther. 2017 Jan 25;19(1):15. doi: 10.1186/s13075-016-1207-7.
  • Rakoczi E, Perge B, Vegh E, Csomor P, Pusztai A et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine. 2016 Dec;83(6):675-679. doi: 10.1016/j.jbspin.2015.10.017.
  • Nagel J, Saxne T, Getborek P, Bengtsson AA, Jacobsen S et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus. 2017 Sep;26(10):1072-1081. doi: 10.1177/0961203317695465.
  • Feldman S, Andrew M, Norris M, McIntyre B, Iyer R. Decline in Rates of Seropositivity for Measles, Mumps, and Rubella Antibodies Among Previously Immunized Children Treated for Acute Leukemia. Clin Infect Dis. 1998 Aug;27(2):388-90.
  • Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001 Jul 15;33(2):139-44. DOI: 10.1086/321805.
  • L'Huillier AG, Posfay Barbe K. Live viral vaccines in transplanted patients. Swiss Med Wkly. 2014 Sep 22;144: w14005. doi: 10.4414/smw.2014.14005.
  • Verolet CM, Posfay-Barbe KM. Live viral vaccines in transplantation: friend or foe? Curr Infect Dis Rep. 2015 Apr;17(4):472. doi: 10.1007/s11908-015-0472-y.
  • Sauerbrei A, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997 Sep;20(5):381-3. DOI: 10.1038/sj.bmt.1700909
  • Chou JF, Kernan NA, Prockop S, Heller G, Scaradavou A et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011 Nov; 17(11): 1708-1713. doi: 10.1016/j. bbmt.2011.05.006.
  • Naidus E, Damon L, Schwartz, BS, Breed C and Liu C. Experience with use of Zostavax® in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am. J. Hematol., 87: 123-125. doi:10.1002/ajh.22196
  • Tsigrelis C, Ljungman P. Vaccinations in patients with hematological malignancies. Blood Rev. 2016 Mar;30(2):139-47. doi: 10.1016/j.blre.2015.10.001.
  • Chong P. P., Avery R. K. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther. 2017 Aug;39(8):1581-1598. doi: 10.1016/j. clinthera.2017.07.005.
  • Ljungman P, Aschan J, Barkholt L, Broliden PA, Gustafsson B et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant. 2004 Oct;34(7):589-93. DOI: 10.1038/sj.bmt.1704634.
  • Miyairi I, Funaki T, SaitohA. Immunization practices in solid organ transplant recipients. Vaccine. 2016 Apr 7;34(16):1958-64. doi: 10.1016/j.vaccine.2016.03.001.
  • Cesaro S, Giacchino M, Fioredda F, Barone A, Battisti L et al. Guidelines on Vaccinations in Paediatric Haematology and Oncology Patients. Biomed Res Int. 2014; 2014: 707691. doi: 10.1155/2014/707691
  • Ljungman P. Vaccination of immunocompromised hosts. In: SA Plotkin, WA Orenstein, PA Offit, eds/ Vaccines, 6th edition, Ed. S. Plotkin, W. Orenstein, and PA. Offit. Philadelphia, PA: Elsevier, .2012 1570 pp SECTION FOUR Vaccination of special groups:1243-1256. eBook ISBN: 9781455737987
  • Bedognetti D, Zoppoli G, Massucco C, Zanardi E, Zupo S. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in Non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011 May 15; 186(10): 6044-6055. doi: 10.4049/ jimmunol.1004095
  • Nicolas C. Issa, and Lindsey R. Baden. Current issues in vaccines for adult patients with hematologic malignancies. J Natl Compr Canc Netw. 2012 Nov 1;10(11):1447-54; quiz 1454.
  • Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination program. Clin Infect Dis. 2016 Jan 15;62(2):139-47. doi: 10.1093/cid/civ803.
Еще
Статья обзорная
SciUp 2024 © 2024 ©